Literature DB >> 15769677

Roles of FGF signaling in skeletal development and human genetic diseases.

Lin Chen1, Chu-Xia Deng.   

Abstract

Fibroblast growth factor receptors (FGFRs) exist as a gene family of 4 membrane bound receptor tyrosine kinases (FGFR1-4) that mediate signals of at least 22 fibroblast growth factors (FGF1-22). FGFs/FGFRs play important roles in multiple biological processes, including mesoderm induction and patterning, cell growth and migration, organ formation and bone growth. Furthermore, it has been shown that missense mutations of FGFR1-3 in human result in, at least, 14 congential bone diseases that are broadly classified into two groups: chondrodysplasia syndromes and craniosynostosis syndromes. The chondrodysplasia affects primarily the skeleton formed through endochondral ossification, resulting short-limbed dwarfisms, while the craniosynostosis affects mainly bones formed through intramembraneous ossification, leading to premature fusion of the craniofacial sutures. Using gene targeting, mouse models mimicking some of these human diseases have been created. Analysis of these mutant mice revealed essential functions of FGFs/FGFRs in skeletal development and maintenance. These models may be beneficial in future studies aimed at developing novel therapeutic strategies for FGFR-related skeletal dysplasias. In this review, we discuss the results of recent studies on FGF receptors to illustrate mechanisms through which the abnormally activated FGF/FGFR signaling results in these diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769677     DOI: 10.2741/1671

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  29 in total

Review 1.  Signaling and transcriptional regulation in osteoblast commitment and differentiation.

Authors:  Wei Huang; Shuying Yang; Jianzhong Shao; Yi-Ping Li
Journal:  Front Biosci       Date:  2007-05-01

Review 2.  Signaling networks that control the lineage commitment and differentiation of bone cells.

Authors:  Carrie S Soltanoff; Shuying Yang; Wei Chen; Yi-Ping Li
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

3.  Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.

Authors:  April N Meyer; Christopher W McAndrew; Daniel J Donoghue
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

4.  Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation.

Authors:  Anne L Jacob; Craig Smith; Juha Partanen; David M Ornitz
Journal:  Dev Biol       Date:  2006-05-27       Impact factor: 3.582

Review 5.  Development of the upper lip: morphogenetic and molecular mechanisms.

Authors:  Rulang Jiang; Jeffrey O Bush; Andrew C Lidral
Journal:  Dev Dyn       Date:  2006-05       Impact factor: 3.780

Review 6.  Kinase mutations in human disease: interpreting genotype-phenotype relationships.

Authors:  Piya Lahiry; Ali Torkamani; Nicholas J Schork; Robert A Hegele
Journal:  Nat Rev Genet       Date:  2010-01       Impact factor: 53.242

7.  Involvement of fibroblast growth factor 18 in dedifferentiation of cultured human chondrocytes.

Authors:  H Yamaoka; S Nishizawa; Y Asawa; Y Fujihara; T Ogasawara; K Yamaoka; S Nagata; T Takato; K Hoshi
Journal:  Cell Prolif       Date:  2009-11-10       Impact factor: 6.831

8.  Analysis of Thisbe and Pyramus functional domains reveals evidence for cleavage of Drosophila FGFs.

Authors:  Sarah Tulin; Angelike Stathopoulos
Journal:  BMC Dev Biol       Date:  2010-08-05       Impact factor: 1.978

9.  The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects.

Authors:  Sara Ota; Zi-Qiang Zhou; Jason M Link; Peter J Hurlin
Journal:  Hum Mol Genet       Date:  2009-04-29       Impact factor: 6.150

Review 10.  MicroRNAs and micromanaging the skeleton in disease, development and evolution.

Authors:  Xinjun He; Johann K Eberhart; John H Postlethwait
Journal:  J Cell Mol Med       Date:  2009-02-09       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.